Multiple studies report that TROP2 is frequently overexpressed in subsets of ovarian cancer, underscoring its potential as a therapeutic target; however, expression levels may vary across tumor subtypes and cohorts, reflecting the heterogeneity characteristic of this disease. Here, TACSTD2 is linked to ovarian cancer.